400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD
Emergent BioSolutions Wins New U.S. Government Contract for ACAM2000® Vaccine
Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Reports Second Quarter 2025 Financial Results
Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
In Re Stockholder Derivative Litigation
Financial Results, Reg. FD
News
Announces Stock Repurchase Program
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
S-1
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
S-8 POS
Definitive Revised Proxy Statement
Submission Upload
Correspondence
Confidential Treatment Order